Treatment of infantile spasms in tuberous sclerosis complex: dismal outcomes but future hope?

Area of Science:

• Neurology
• Pediatrics
• Genetics

Background:

• Tuberous sclerosis complex (TSC) is a genetic disorder associated with neurological complications, including infantile spasms.
• Infantile spasms in TSC often present with severe cognitive impairment and intractable epilepsy, posing significant treatment challenges.
• Vigabatrin is a first-line treatment for infantile spasms, but its long-term efficacy in TSC patients remains under investigation.

Purpose of the Study:

• To analyze electroencephalogram (EEG) findings in children with infantile spasms and TSC.
• To identify predictors of cognitive outcome in this patient population.
• To evaluate the effectiveness of current treatment strategies, including vigabatrin and adrenocorticotropic hormone (corticotropin).

Main Methods:

• Retrospective study analyzing EEG results and clinical outcomes.
• Identification of factors associated with cognitive impairment and seizure control.
• Comparison of treatment responses to vigabatrin and corticotropin.

Main Results:

• Worsening hypsarrhythmia, abnormal EEG background activity, and incomplete vigabatrin response predicted poor cognitive outcomes.
• The majority of patients experienced cognitive impairment and intractable epilepsy, regardless of treatment.
• A minority of patients achieved prolonged seizure freedom (>1 year) or mild/no cognitive impairment.

Conclusions:

• Infantile spasms in TSC present significant challenges, with a high prevalence of poor cognitive and seizure outcomes.
• While vigabatrin shows short-term efficacy, its long-term impact is limited in many TSC patients.
• Novel therapeutic strategies are crucial for improving outcomes in children with TSC-associated infantile spasms.